Since SFRP4 expression has been shown to be lost in a large majority of ovarian cancer patients [18], this raises the possibility that modulation of Wnt signalling through SFRP4 or other upstream Wnt pathway members may represent a new avenue for targeted therapy in ovarian cancer. This evidence concerns the gene SFRP4 and ovarian cancer.